finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Adagene stock

Own Adagene stock in just a few minutes.

Buy Adagene Inc (ADAG)
Fact checked

Adagene Inc wrapped up its $139.73 million initial public offering, selling 7,354,000 American depositary shares at $19 each. The stock opened at $20.40 when trading began Tuesday and skyrocketed by more than 45% in early trading.

How to buy shares in Adagene

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ADAG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

What's in this guide?

  1. ADAG shares summary
  2. Compare share dealing platforms
  3. Is ADAG stock a buy or sell?
  4. Stock performance over time
  5. Can I short ADAG shares?
  6. Adagene's financials
  7. Does Adagene pay a dividend?
  8. Other common questions

Adagene share price

Use our graph to track the performance of ADAG stocks over time.

Adagene shares at a glance

Information last updated 2021-03-24.
52-week range$17.51 - $31.83
50-day moving average $23.82
200-day moving average $23.82
Wall St. target price$32.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Adagene shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Go to site
More Info
Robinhood
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Go to site
More Info
Interactive Brokers
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Go to site
More Info
Webull
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Go to site
More Info
Public
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
Go to site
More Info
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Adagene stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Adagene Inc. by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adagene financials

Revenue TTM $789,500
Gross profit TTM $480,000
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $748.3 million

TTM: trailing 12 months

Shorting Adagene shares

There are currently 21,479 Adagene shares held short by investors – that's known as Adagene's "short interest". This figure is 119.5% up from 9,786 last month.

There are a few different ways that this level of interest in shorting Adagene shares can be evaluated.

Adagene's "short interest ratio" (SIR)

Adagene's "short interest ratio" (SIR) is the quantity of Adagene shares currently shorted divided by the average quantity of Adagene shares traded daily (recently around 1.1 million). Adagene's SIR currently stands at 0.02. In other words for every 100,000 Adagene shares traded daily on the market, roughly 20 shares are currently held short.

To gain some more context, you can compare Adagene's short interest ratio against those of similar companies.

However Adagene's short interest can also be evaluated against the total number of Adagene shares, or, against the total number of tradable Adagene shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adagene's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Adagene shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Adagene shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adagene.

Find out more about how you can short Adagene stock.

Adagene share dividends

We're not expecting Adagene to pay a dividend over the next 12 months.

You may also wish to consider:

Adagene overview

Adagene Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China. .

  1. Technical analysis graphic from TradingView, https://uk.tradingview.com Stock prices and other date from EOD Historical Data

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site